Literature DB >> 1910154

Exercise in hemodialysis patients after treatment with recombinant human erythropoietin.

A P Lundin1, M J Akerman, R M Chesler, B G Delano, N Goldberg, R A Stein, E A Friedman.   

Abstract

To assess the effect of substantial increases in blood hemoglobin (Hb) caused by treatment with recombinant human erythropoietin (rhEPO) on exercise capacity in maintenance hemodialysis patients, we evaluated 10 patients (7 men and 3 women) at a mean age of 44.3 +/- 8.4 years on maintenance hemodialysis for a mean of 29.7 +/- 30.2 months by treadmill exercise to exhaustion. The patients were tested before administration of rhEPO and after a minimum 1 g/dl rise in Hb. With a change in Hb from 7.1 +/- 1.4 to 9.8 +/- 2.1 g/dl, peak oxygen consumption (VO2 peak) with exercise increased 50.3 +/- 9% (T1 = 15.1 +/- 5.3, T2 = 22.7 +/- 4.6 ml O2/kg/min, p less than 0.05). Respiratory exchange ratio (RER) at a given submaximal exercise level (3 mph, 6% of elevation) decreased significantly (T1 = 1.13 +/- 0.24, T2 = 0.92 +/- 0.08, p less than 0.05). The rhEPO-mediated increase in Hb was associated with an increased VO2 peak--an improvement of the peak exercise capacity and a reduced submaximal RER--reflecting a reduction in anaerobic metabolism at activities of daily living.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910154     DOI: 10.1159/000186443

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

Review 1.  Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.

Authors:  D C Harris
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

Review 2.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 3.  A review of quality of life in chronic renal failure.

Authors:  D S Parsons; D C Harris
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

4.  Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure.

Authors:  R M Marrades; J Roca; J M Campistol; O Diaz; J A Barberá; J V Torregrosa; J R Masclans; A Cobos; R Rodríguez-Roisin; P D Wagner
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

5.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.